Khachatryan Davit, Groll Dianne, Booij Linda, Sepehry Amir A, Schütz Christian G
Queen's University Department of Psychiatry, Providence Care, Mental Health Services, 752 King Street West, Postal Bag 603, Kingston, ON, K7L 7X3, Canada.
University of Concordia, Department of Psychology Richard J. Renaud Science Complex, 7141 Sherbrooke W.
Gen Hosp Psychiatry. 2016 Mar-Apr;39:46-52. doi: 10.1016/j.genhosppsych.2015.10.007. Epub 2015 Nov 1.
Posttraumatic stress disorder (PTSD) is a disorder with significant sleep morbidity and limited treatment options. Prazosin may constitute a novel management approach and has been tested recently in a number of trials. We conducted a meta-analysis to examine the effectiveness of prazosin for nightmares and other sleep disturbances in adults with PTSD.
A systematic review of databases for randomized, double-blind, placebo-controlled trials of adults diagnosed with PTSD and reporting sleep disturbances that were treated with prazosin was conducted in January 2015. No limitations were placed on language or year of publication.
Six randomized controlled trials of prazosin for sleep disturbances in patients with PTSD were included (sample n=240). We found that prazosin was statistically significantly more effective than placebo in improving sleep quality [g=0.987, 95% confidence interval (CI): 0.324-1.651] and in reducing overall PTSD symptoms (g=0.699, 95% CI: 0.139-1.260) and sleep disturbances in particular (g=0.799, 95% CI: 0.391-1.234).
Prazosin showed medium-to-large and statistically significant effects on PTSD symptoms in general and sleep disturbances in particular. While promising, results should be interpreted with caution given the limited total number of participants and the limitations induced by the majority of participants being male and noncivilian.
创伤后应激障碍(PTSD)是一种存在显著睡眠问题且治疗选择有限的疾病。哌唑嗪可能构成一种新的治疗方法,最近已在多项试验中进行了测试。我们进行了一项荟萃分析,以检验哌唑嗪对患有PTSD的成年人噩梦及其他睡眠障碍的有效性。
2015年1月对诊断为PTSD且报告有睡眠障碍并接受哌唑嗪治疗的成年人的随机、双盲、安慰剂对照试验数据库进行了系统评价。对语言或出版年份未设限制。
纳入了6项关于哌唑嗪治疗PTSD患者睡眠障碍的随机对照试验(样本量n = 240)。我们发现,在改善睡眠质量方面,哌唑嗪在统计学上显著优于安慰剂[g = 0.987,95%置信区间(CI):0.324 - 1.651],在减轻总体PTSD症状方面(g = 0.699,95% CI:0.139 - 1.260),尤其是在减少睡眠障碍方面(g = 0.799,95% CI:0.391 - 1.234)。
哌唑嗪对PTSD症状总体上,尤其是对睡眠障碍显示出中到较大且具有统计学意义的效果。虽然前景乐观,但鉴于参与者总数有限以及大多数参与者为男性且非平民所带来的局限性,结果应谨慎解读。